Covid-19 vaccine candidate: Novasep signs a Master Supply and Development Agreement with AstraZeneca | Novasep - Nov. 12, 2020 |

Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce that it has now signed a multi-year Master Supply and Development Agreement with AstraZeneca to support large-scale production of the active substance of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222.

This new contract follows the initial agreement signed between AstraZeneca and Novasep Belgium on June 14th in the context of the Inclusive Alliance for Vaccines (IAV), whose members are France, Germany, Italy and the Netherlands.  [Who was late at the table BoJo? ... honor British commitments]

The production of the vaccine candidate active substance under this supply agreement will be carried out at Novasep's site located in Seneffe, Belgium which expects to increase its workforce from 280 to close to 400 by 2021 to support this project.

AstraZeneca COVID-19 Vaccine (AZD1222) Distribution

On December 8, 2020, Halix B.V. announced it would provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. HALIX expands with 2 additional viral vector production lines to meet the increased demand.

Halix - Excellence in GMP Manufacturing

The 6,700 m2 BSL2 GMP facility, recently approved by the Dutch authorities and located on the Leiden Bio Science Park in the Netherlands, provides both clinical and commercial scale manufacturing capabilities in fully independent, self-contained Grade B and C cleanrooms for virus products.

'Sapere aude'